Gathering the record
Relay is organizing the evidence and source boundaries.
Porcine-brain-derived peptide and amino-acid mixture
Cerebrolysin is a standardized injectable mixture of low-molecular-weight porcine brain peptides and amino acids. Controlled studies have explored stroke, traumatic brain injury, and dementia, but results vary by trial and population, and it is not FDA approved.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Cerebrolysin is an injectable mixture of small peptides and amino acids made from porcine brain tissue. It is marketed for neurologic conditions in some countries but is not FDA approved.
Researchers have asked whether the mixture can support recovery after stroke or traumatic brain injury, or affect decline in dementia. Because it is a mixture, consistent manufacturing and trial-specific context matter.
Controlled human evidence is mixed. The large CASTA acute-stroke trial found no significant overall benefit, while a smaller rehabilitation study reported motor signals. Traumatic-brain-injury and dementia trials also produced setting-specific findings that have not formed one consistent efficacy record.
Which patients, if any, gain a reproducible meaningful benefit; how timing and rehabilitation change outcomes; and whether different lots or country-specific products are comparable remain unresolved. No evidence establishes healthy-cognition or general neuroprotection effects.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A large multicenter trial investigated Cerebrolysin as an addition to standard care in adults with acute ischemic stroke, comparing it with placebo under blinded conditions.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Randomized trials span stroke, traumatic brain injury, and dementia, including a large acute-stroke trial.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The large CASTA trial was neutral overall while smaller studies reported selected benefits.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The primary overall efficacy comparison was neutral; a more severe subgroup produced only a hypothesis-forming signal. The stroke result cannot establish benefit in dementia, traumatic brain injury, healthy cognition, or other formulations. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple randomized controlled trials exist, including the large 1,070-participant CASTA acute-stroke study; however, the overall efficacy record is mixed and indication-specific.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Which patient groups, if any, obtain reproducible clinically meaningful benefit, and how lot composition, co-interventions, timing, and country-specific formulations affect outcomes and safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Its identity and biological activity belong to a standardized mixture, so claims about one active molecule or receptor are misleading.
A post hoc severe-stroke subgroup signal should not replace the neutral overall result.
These findings justify continued research but do not resolve the inconsistency across the broader evidence base.
Older trials reported symptom-scale signals; they do not show durable modification of underlying neurodegeneration.
Research in stroke, TBI, or dementia cannot be converted into claims for focus, memory enhancement, or general brain optimization.
FDA records explicitly separate substance identity and orphan history from approval.
Mixture composition, concentration, sterility, infusion conditions, and clinical monitoring are formulation-specific.
Mechanisms
Cerebrolysin is a hydrolysate-derived biological mixture rather than one molecular entity. Human trials span acute ischemic stroke, post-stroke rehabilitation, traumatic brain injury, Alzheimer disease, and vascular dementia. The large CASTA acute-stroke trial did not show a significant overall benefit on its primary outcome, while smaller rehabilitation and TBI studies reported signals on selected functional or global outcomes. Heterogeneous designs, modest samples, regional practice differences, mixture identity, and limited independent replication constrain transferability. FDA substance indexing and an orphan designation record document identity and regulatory history but do not constitute U.S. marketing approval.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled neurorecovery trial
Adults with moderate-to-severe traumatic brain injury
CAPTAIN II reported a favorable multidimensional outcome signal and similar overall safety between groups.
Study administration: Cerebrolysin or placebo added to standard care
Limitations: The composite analysis, modest sample, and regional care settings limit certainty about effect size and generalizability.
Randomized, double-blind, placebo-controlled multicenter trial
Adults beginning rehabilitation after ischemic stroke
CARS reported better motor-function and global outcomes in the Cerebrolysin group during early rehabilitation.
Study administration: Cerebrolysin or placebo alongside standardized rehabilitation
Limitations: The trial was smaller than CASTA, focused on a selected rehabilitation population, and does not establish broad acute-stroke efficacy.
Randomized controlled clinical study
Adults with mild traumatic brain injury
The study reported improved cognitive recovery at three months, especially on long-term-memory measures.
Study administration: Cerebrolysin plus usual care versus comparison care
Limitations: The sample was small and the finding needs larger independent replication with modern TBI outcome standards.
Randomized, double-blind, placebo-controlled multicenter trial
Adults with acute ischemic stroke in Asia
CASTA did not show a significant overall benefit on the primary global outcome. A more severely affected subgroup generated a hypothesis-forming signal.
Study administration: Cerebrolysin or placebo added to standard stroke care
Limitations: The overall neutral result is primary. Subgroup findings were not the main prespecified efficacy conclusion and require independent confirmation.
Randomized, double-blind, placebo-controlled study
Adults with mild-to-moderate Alzheimer disease
The trial reported selected cognitive and global benefits, with adverse events occurring in both groups.
Study administration: Intravenous Cerebrolysin or placebo
Limitations: Older trial methods, repeated-course designs, and inconsistent findings across dementia studies prevent a simple efficacy conclusion.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved; marketed for neurological indications in some countries Which patient groups, if any, obtain reproducible clinically meaningful benefit, and how lot composition, co-interventions, timing, and country-specific formulations affect outcomes and safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2020-01-01 · PMID 31897941
2016-04-05
2016-01-01 · PMID 26564102
2013-01-01 · PMID 23656173
2012-01-01 · PMID 22282884
2009-03-26 · NCT00868283
2002-01-01 · PMID 12111446